Evidence map›Paper›PMID 26147622›Full record

ArticlePLoS genetics2015

In vivo Modeling Implicates APOL1 in Nephropathy: Evidence for Dominant Negative Effects and Epistasis under Anemic Stress.

Blair R Anderson, David N Howell, Karen Soldano, Melanie E Garrett, Nicholas Katsanis, Marilyn J Telen, Erica E Davis, Allison E Ashley-Koch

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Lessons From APOL1 Animal Models.Frontiers in medicine · 2021
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. APOL1 and kidney cell function.American journal of physiology. Renal physiology · 2019
    Review
  16. Article
  17. APOL1-Associated Nephropathy: A Key Contributor to Racial Disparities in CKD.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2018
    Review
  18. Review
  19. Review
  20. HDL in CKD-The Devil Is in the Detail.Journal of the American Society of Nephrology : JASN · 2018
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Blair R AndersonCenter for Human Disease Modeling, Duke University Medical Center, Durham, North Carolina, United States of America.
David N HowellDepartment of Pathology, Division of Pathology Clinical Services, Duke University, Durham, North Carolina, United States of America.
Karen SoldanoCenter for Human Disease Modeling, Duke University Medical Center, Durham, North Carolina, United States of America.
Melanie E GarrettCenter for Human Disease Modeling, Duke University Medical Center, Durham, North Carolina, United States of America.
Nicholas KatsanisCenter for Human Disease Modeling, Duke University Medical Center, Durham, North Carolina, United States of America.
Marilyn J TelenDepartment of Medicine, Division of Hematology, Duke University Medical Center, Durham, North Carolina, United States of America.
Erica E DavisCenter for Human Disease Modeling, Duke University Medical Center, Durham, North Carolina, United States of America.
Allison E Ashley-KochCenter for Human Disease Modeling, Duke University Medical Center, Durham, North Carolina, United States of America.
Duke Medical Center · USDuke University · USDuke University Hospital · US

Funding

Genetics Training Grant-Year 26T32GM007754 · NIGMS · DUKE UNIVERSITY · PI HAASE, STEVEN B · 1985 to 2019
$8.3M
Renal Genomics CoreP30DK096493 · NIDDK · DUKE UNIVERSITY · PI WINN, MICHELLE P. · 2012 to 2016
$5.9M
Research Project 3P50DK096415 · NIDDK · DUKE UNIVERSITY · PI KATSANIS, NICHOLAS · 2012 to 2016
$4.2M
Outcome Modifying Genes in Sickle Cell DiseaseR01HL068959 · NHLBI · DUKE UNIVERSITY · PI TELEN, MARILYN J · 2001 to 2005
$3.6M
NHLBI NIH HHS R01 HL068959NHLBI NIH HHS R01HL068959NIDDK NIH HHS P30 DK096493NIDDK NIH HHS P50 DK096415NIGMS NIH HHS T32 GM007754Wellcome Trust
6 · The paper itself

Abstract

African Americans have a disproportionate risk for developing nephropathy. This disparity has been attributed to coding variants (G1 and G2) in apolipoprotein L1 (APOL1); however, there is little functional evidence supporting the role of this protein in renal function. Here, we combined genetics and in vivo modeling to examine the role of apol1 in glomerular development and pronephric filtration and to test the pathogenic potential of APOL1 G1 and G2. Translational suppression or CRISPR/Cas9 genome editing of apol1 in zebrafish embryos results in podocyte loss and glomerular filtration defects. Complementation of apol1 morphants with wild-type human APOL1 mRNA rescues these defects. However, the APOL1 G1 risk allele does not ameliorate defects caused by apol1 suppression and the pathogenicity is conferred by the cis effect of both individual variants of the G1 risk haplotype (I384M/S342G). In vivo complementation studies of the G2 risk allele also indicate that the variant is deleterious to protein function. Moreover, APOL1 G2, but not G1, expression alone promotes developmental kidney defects, suggesting a possible dominant-negative effect of the altered protein. In sickle cell disease (SCD) patients, we reported previously a genetic interaction between APOL1 and MYH9. Testing this interaction in vivo by co-suppressing both transcripts yielded no additive effects. However, upon genetic or chemical induction of anemia, we observed a significantly exacerbated nephropathy phenotype. Furthermore, concordant with the genetic interaction observed in SCD patients, APOL1 G2 reduces myh9 expression in vivo, suggesting a possible interaction between the altered APOL1 and myh9. Our data indicate a critical role for APOL1 in renal function that is compromised by nephropathy-risk encoding variants. Moreover, our interaction studies indicate that the MYH9 locus is also relevant to the phenotype in a stressed microenvironment and suggest that consideration of the context-dependent functions of both proteins will be required to develop therapeutic paradigms.

Indexed as

AnimalsApolipoprotein L1ApolipoproteinsClustered Regularly Interspaced Short Palindromic RepeatsFlow CytometryGene Knockdown TechniquesGenetic Predisposition to DiseaseGenetic VariationGlomerular Filtration RateGlomerulonephritis, MembranousHumansKidney GlomerulusLipoproteins, HDLMicroscopy, Electron, TransmissionMolecular Motor ProteinsMorpholinosAPOL1 protein, humanApolipoprotein L1ApolipoproteinsLipoproteins, HDLMolecular Motor ProteinsMorpholinosMYH9 protein, humanMyosin Heavy Chains

Identifiers

PMID26147622
PMCPMC4492502
OpenAlexW2157826979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.